Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00197431 |
Recruitment Status
: Unknown
Verified December 2003 by Hamamatsu University.
Recruitment status was: Recruiting
First Posted
: September 20, 2005
Last Update Posted
: March 22, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Gastric Cancer Esophageal Cancer Pancreatic Cancer Colon Cancer | Drug: S-1 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Pharmacokinetic and Pharmacodynamic Study of S-1 and Its Effects in Patients With the Digestive Organ Cancer With Reference to Genetic Polymorphism and Activity of CYP2A6 and DPD |
Study Start Date : | January 2004 |
- Whether the differences in activities of CYP2A6 and DPD affect pharmacokinetics and pharmacodynamics of S-1 and clinical outcomes
- Side effect and motility of patients treated with S-1

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 85 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Patients with digestive organ cancer
Exclusion Criteria:
- Patients without digestive organ cancer

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00197431
Contact: Naohito Shirai, MD., PhD | 81-534-2788 | naohito@hama-med.ac.jp |
Japan | |
Hamamatsu University School of Medicine | Recruiting |
Hamamatsu, Shizuoka, Japan, 431-3192 | |
Contact: Naohito Shirai, MD., PhD 81-534-2870 naohito@hama-med.ac.jp | |
Principal Investigator: Takahisa Furuta, MD., PhD |
Study Chair: | Naohito Shirai, MD., PhD | Department Laboratory Medicine, Hamamatsu University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00197431 History of Changes |
Other Study ID Numbers: |
S-12005 |
First Posted: | September 20, 2005 Key Record Dates |
Last Update Posted: | March 22, 2006 |
Last Verified: | December 2003 |
Additional relevant MeSH terms:
Pancreatic Neoplasms Stomach Neoplasms Esophageal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases |
Pancreatic Diseases Endocrine System Diseases Gastrointestinal Neoplasms Gastrointestinal Diseases Stomach Diseases Head and Neck Neoplasms Esophageal Diseases |